108 related articles for article (PubMed ID: 33502425)
1. Multivalency in CXCR4 chemokine receptor targeted iron oxide nanoparticles.
Baghdadi NE; Burke BP; Alresheedi T; Nigam S; Saeed A; Almutairi F; Domarkas J; Khan A; Archibald SJ
Dalton Trans; 2021 Feb; 50(5):1599-1603. PubMed ID: 33502425
[TBL] [Abstract][Full Text] [Related]
2. The CXCR4 agonist ligand stromal derived factor-1 maintains high affinity for receptors in both Galpha(i)-coupled and uncoupled states.
Di Salvo J; Koch GE; Johnson KE; Blake AD; Daugherty BL; DeMartino JA; Sirotina-Meisher A; Liu Y; Springer MS; Cascieri MA; Sullivan KA
Eur J Pharmacol; 2000 Dec; 409(2):143-54. PubMed ID: 11104827
[TBL] [Abstract][Full Text] [Related]
3. Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions.
Bobkov V; Zarca AM; Van Hout A; Arimont M; Doijen J; Bialkowska M; Toffoli E; Klarenbeek A; van der Woning B; van der Vliet HJ; Van Loy T; de Haard H; Schols D; Heukers R; Smit MJ
Biochem Pharmacol; 2018 Dec; 158():413-424. PubMed ID: 30342023
[TBL] [Abstract][Full Text] [Related]
4. Cloning and characterizing mutated human stromal cell-derived factor-1 (SDF-1): C-terminal alpha-helix of SDF-1alpha plays a critical role in CXCR4 activation and signaling, but not in CXCR4 binding affinity.
Tan Y; Du J; Cai S; Li X; Ma W; Guo Z; Chen H; Huang Z; Xiao J; Cai L; Cai S
Exp Hematol; 2006 Nov; 34(11):1553-62. PubMed ID: 17046575
[TBL] [Abstract][Full Text] [Related]
5. A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4.
Schoofs G; Van Hout A; D'huys T; Schols D; Van Loy T
J Vis Exp; 2018 Mar; (133):. PubMed ID: 29578516
[TBL] [Abstract][Full Text] [Related]
6. Bivalent 14-mer peptide ligands of CXCR4 with polyproline linkers with anti-chemotactic activity against Jurkat cells.
Tanaka T; Aoki T; Nomura W; Tamamura H
J Pept Sci; 2017 Jul; 23(7-8):574-580. PubMed ID: 28078743
[TBL] [Abstract][Full Text] [Related]
7. Chemokine CXCL12 induces binding of ferritin heavy chain to the chemokine receptor CXCR4, alters CXCR4 signaling, and induces phosphorylation and nuclear translocation of ferritin heavy chain.
Li R; Luo C; Mines M; Zhang J; Fan GH
J Biol Chem; 2006 Dec; 281(49):37616-27. PubMed ID: 17056593
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1alpha: implications for development of selective CXCR4 antagonists.
Gupta SK; Pillarisetti K; Thomas RA; Aiyar N
Immunol Lett; 2001 Aug; 78(1):29-34. PubMed ID: 11470148
[TBL] [Abstract][Full Text] [Related]
9. Fluorescent CXCR4 chemokine receptor antagonists: metal activated binding.
Khan A; Silversides JD; Madden L; Greenman J; Archibald SJ
Chem Commun (Camb); 2007 Jan; (4):416-8. PubMed ID: 17220989
[TBL] [Abstract][Full Text] [Related]
10. New AMD3100 derivatives for CXCR4 chemokine receptor targeted molecular imaging studies: synthesis, anti-HIV-1 evaluation and binding affinities.
Poty S; Désogère P; Goze C; Boschetti F; D'huys T; Schols D; Cawthorne C; Archibald SJ; Maëcke HR; Denat F
Dalton Trans; 2015 Mar; 44(11):5004-16. PubMed ID: 25640878
[TBL] [Abstract][Full Text] [Related]
11. Microtiter plate-based antibody-competition assay to determine binding affinities and plasma/blood stability of CXCR4 ligands.
Harms M; Gilg A; Ständker L; Beer AJ; Mayer B; Rasche V; Gruber CW; Münch J
Sci Rep; 2020 Sep; 10(1):16036. PubMed ID: 32994431
[TBL] [Abstract][Full Text] [Related]
12. Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors.
Van Hout A; D'huys T; Oeyen M; Schols D; Van Loy T
PLoS One; 2017; 12(4):e0176057. PubMed ID: 28410420
[TBL] [Abstract][Full Text] [Related]
13. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
Khare T; Bissonnette M; Khare S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles.
Chittasupho C; Lirdprapamongkol K; Kewsuwan P; Sarisuta N
Eur J Pharm Biopharm; 2014 Oct; 88(2):529-38. PubMed ID: 25119723
[TBL] [Abstract][Full Text] [Related]
15. Magnetic nanoparticles of Ga-substituted ε-Fe
Královec K; Havelek R; Koutová D; Veverka P; Kubíčková L; Brázda P; Kohout J; Herynek V; Vosmanská M; Kaman O
J Biomed Mater Res A; 2020 May; 108(7):1563-1578. PubMed ID: 32176405
[TBL] [Abstract][Full Text] [Related]
16. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
Berning P; Schaefer C; Clemens D; Korsching E; Dirksen U; Potratz J
Cell Commun Signal; 2018 May; 16(1):21. PubMed ID: 29776413
[TBL] [Abstract][Full Text] [Related]
17. Disruption of Cell Adhesion and Cytoskeletal Networks by Thiol-Functionalized Silica-Coated Iron Oxide Nanoparticles.
Královec K; Melounková L; Slováková M; Mannová N; Sedlák M; Bartáček J; Havelek R
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33302486
[TBL] [Abstract][Full Text] [Related]
18. A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II.
Zhou N; Luo Z; Luo J; Hall JW; Huang Z
Biochemistry; 2000 Apr; 39(13):3782-7. PubMed ID: 10736178
[TBL] [Abstract][Full Text] [Related]
19. Biased antagonism of CXCR4 avoids antagonist tolerance.
Hitchinson B; Eby JM; Gao X; Guite-Vinet F; Ziarek JJ; Abdelkarim H; Lee Y; Okamoto Y; Shikano S; Majetschak M; Heveker N; Volkman BF; Tarasova NI; Gaponenko V
Sci Signal; 2018 Oct; 11(552):. PubMed ID: 30327409
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of the CXCR4 chemokine receptor in human T cell lines: ligand binding, biological activity, and HIV-1 infectivity.
Hesselgesser J; Liang M; Hoxie J; Greenberg M; Brass LF; Orsini MJ; Taub D; Horuk R
J Immunol; 1998 Jan; 160(2):877-83. PubMed ID: 9551924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
